NICE publishes positive Final Appraisal Determination for dapagliflozin

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) for Bristol-Myers Squibb and AstraZeneca’s, first-in-class Type 2 diabetes medicine FORXIGA® (dapagliflozin).

Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news